Vectura expanding manufacturing capabilities in Chippenham

The company offers services to advance dry powder programmes from early development through clinical phases of development to small-scale commercialisation

Inhalation CDMO, Vectura Group, has announced an expansion of its dry powder inhaler (DPI) development and manufacturing capabilities at its facility in Chippenham, UK.

Investment has been made at the site to install a capsule filler, a capsule blister packer, and a Mikron semi-automated device assembly machine. These enhancements will support work with capsule inhaler devices, Vectura’s open inhale close (OIC) device, and the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which was recently approved by FDA.

These capabilities are scheduled to be available from Q2 2021.The expansion will significantly expand the company’s offering in DPI dosage form development, both unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programmes.

The semi-automated device assembly line will help meet demand for Vectura’s blister-based, multi-dose DPI devices, offering increased capacity to manufacture up to one million devices per year.

With formulation services including engineered particle development, DPI device design and development, advanced inhalation analytics and GMP product and device manufacturing, customers can partner with Vectura to advance dry powder programmes from early development through clinical phases of development to small-scale commercialisation.

Mark Bridgewater, CCO, Vectura, said: “Vectura has extensive specialist knowledge and experience in the development of dry powder inhalers, and this investment allows us to fully integrate these disciplines under one roof for pre-clinical, clinical and commercial programmes.” He added, “The investment in new equipment will complement existing blister-based platform capabilities to offer customers greater flexibility, alongside our other inhalation delivery platforms, to provide patients with new inhaled therapies.”

Companies